Pladienolide B
Chemical Name: (4R,7R,8S,9E,11S,12S)-8-(Acetyloxy)-4,7-dihydroxy-12-[(1E,3E,5S)-6-[(2R,3R)-3-[(1R,2S)-2-hydroxy-1-methylbutyl]-2-oxiranyl]-1,5-dimethyl-1,3-hexadien-1-yl]-7,11-dimethyloxacyclododec-9-en-2-one
Purity: ≥95%
Biological Activity
Pladienolide B is a mRNA splicing inhibitor that decreases splicing capacity up to 75% in vitro. Pladienolide B directly targets splicesome-associated 130 (SAP130), inhibits splicing factor 3B subunit (SF3B1) and impairs U2 small nuclear ribonucleoprotein (U2 snRNP) interaction with pre-mRNA. Pladienolide B arrests the cell cycle in G1 and G2/M phases and displays antitumor activity against gastric cancer cells (IC50 values are 1.6-4.9 nM). Transient treatment with pladienolide B can reprogram pluripotent hESCs into a distinct type of zigotic genome activation (ZGA)-like cells (ZLCs). Cell permeable and active in vivo.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Background References
-
Splicing controls the ubiquitin response during DNA double-strand break repair.
Pederiva C, Bohm S, Julner A, Farnebo M.
Cell Death Differ -
Therapeutic targeting of splicing in cancer.
Lee et al.
Nature Medicine, 2016;22:976 -
High antitumor activity of pladienolide B and its derivative in gastric cancer.
Sato et al.
Cancer Sci., 2014;105:110
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for Pladienolide B
The citations listed below are publications that use Tocris products. Selected citations for Pladienolide B include:
10 Citations: Showing 1 - 10
-
Capturing totipotency in human cells through spliceosomal repression.
Authors: Li Et al.
Cell 2024;187:3284
-
Highly efficient generation of blastocyst-like structures from spliceosomes-repressed mouse totipotent blastomere-like cells.
Authors: Wenjing Et al.
Sci China Life Sci 2023;66:423-435
-
8C-like cells capture the human zygotic genome activation program in vitro.
Authors: Wolf Et al.
Cell Stem Cell 2022;29:449-459.e6
-
Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
Authors: Frank Et al.
J Biol Chem 2021;297:101277
-
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Authors: Jing Et al.
Cell 2021;184:4032-4047.e31
-
ATR Protects the Genome against R Loops through a MUS81-Triggered Feedback Loop.
Authors: Lee Et al.
Mol Cell 2020;77:514-527.e4
-
Small molecule modulators of pre-mRNA splicing in cancer therapy.
Authors: Salton Et al.
Trends Mol.Med. 2016;22:28
-
RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML.
Authors: Crews Et al.
Cell stem cell 2016;19:599
-
Short-circuiting RNA splicing.
Authors: Disney Et al.
Nat.Chem.Biol. 2008;4:723
-
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
Authors: Kotake Et al.
Nat.Chem.Biol. 2007;3:570
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for Pladienolide B
There are currently no reviews for this product. Be the first to review Pladienolide B and earn rewards!
Have you used Pladienolide B?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image